
|Videos|November 3, 2021
Oral testosterone undecanoate shows promising results for first use in the real world
Author(s)Urology Times staff
“We were surprised to see that the majority of subjects in these simulations had testosterone levels within eugonadal range for all 3 dose's studies,” says Jay Newmark, MD, MBA.
Advertisement
In this video, Jay Newmark, MD, MBA, discusses the background, findings, and takeaways of the study, “Real-World Experience with First FDA-Approved Oral Testosterone Undecanoate Formulation,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Newmark is a chief medical officer at Clarus Therapeutics, Northbrook, Illinois.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Perioperative Treatment for High-Risk Localized Prostate Cancer, With Keyan Salari, MD, PhD
2
Ac-225 rosopatamab tetraxetan shows promising activity in Lu-PSMA–pretreated mCRPC
3
Sanoj Punnen, MD, on balancing ADT efficacy with cardiovascular safety
4
Evolving Systemic Therapies in mCSPC
5













